Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
- Registration Number
- NCT04956276
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Brief Summary
This is a Phase 2, multiple ascending, dose-finding, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, health-related quality of life, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity, of up to 3 dose regimens of ALXN1830 administered subcutaneous(ly) (SC) in the treatment of WAIHA.
This study will include 2 randomized, double-blind, placebo-controlled cohorts (Cohorts 1 and 2) to evaluate an 8-week treatment regimen, and an optional third open-label cohort (Cohort 3) to evaluate an alternative 12-week dosing regimen. Participants may continue participation in this study at the participant's and investigator's discretion in an open-label extension (OLE) period, consisting of monthly visits to observe participants for relapse, which will require going back on active treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
-
Diagnosed with primary or secondary WAIHA at least 6 weeks prior to Screening.
-
Failed or have not tolerated at least one prior WAIHA treatment regimen, for example, corticosteroids, rituximab, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, danazol, or vincristine.
-
Hemoglobin < 10 g/dL and ≥ 6 g/dL at Screening.
-
Positive direct antiglobulin test (Coombs) (IgG positive who are positive or negative for the presence of complement C3) at Screening.
-
Evidence of active hemolysis including any one of the below:
- LDH > upper limit of normal (ULN) or
- Haptoglobin < lower limit of normal or
- Indirect bilirubin > ULN
- Total IgG > 500 mg/dL at Screening
- Platelet count ≥ 75 x 10^9/liter (L)
- Absolute neutrophil count greater than 1.0 x 10^9/L
Key
- Participants with Evan's syndrome.
- Human immunodeficiency virus (HIV) infection (positive HIV 1 or HIV 2 antibody test).
- Positive hepatitis B surface antigen or hepatitis C antibody test.
- Inability to travel to the clinic for specified visits during the Primary Treatment Period or fulfill the logistical requirements of study intervention administration.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 2: ALXN1830/Placebo ALXN1830 Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period. Cohort 2: ALXN1830/Placebo Placebo Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period. Cohort 1: ALXN1830/Placebo ALXN1830 Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period. Cohort 1: ALXN1830/Placebo Placebo Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period. Cohort 3: ALXN1830 ALXN1830 If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
- Primary Outcome Measures
Name Time Method Proportion Of Participants Achieving A ≥ 2 Grams/Deciliter (g/dL) Increase In Hemoglobin (Hgb) From Baseline To The End Of Primary Treatment Baseline through Week 12 Participants will have to achieve this increase without requiring any increase in the dose of an existing WAIHA medication after Day 1 (baseline) and without packed red blood cells (pRBC) transfusions after Day 14.
- Secondary Outcome Measures
Name Time Method Change From Baseline To The End Of Primary Treatment In Serum Lactate Dehydrogenase (LDH) Levels Baseline, Week 12 Total Corticosteroid Usage From Baseline To The End Of Primary Treatment Baseline, Week 12 Number Of Days To Reach Corticosteroid Discontinuation From The End Of Primary Treatment To The End Of Follow Up After Primary Treatment Week 12 through Week 20 Incidence And Titers Of Neutralizing Antibodies Against ALXN1830 Over Time Up to 2 years Change From Baseline Of IgG Subtypes (IgG1 4) By Dose Group And Time Point Up to 2 years Change From Baseline Of Circulating Immune Complexes By Dose Group And Time Point Up to 2 years Incidence And Titers Of Anti-drug Antibodies Against ALXN1830 Over Time Up to 2 years Change From Baseline Of IgA By Dose Group And Time Point Up to 2 years Total Number Of Units Of pRBCs Transfused Baseline through Week 12 Number Of Hgb Measurements ≥ 2 g/dL From Baseline To The End Of Primary Treatment Baseline, Week 12 Change From Baseline To The End Of Primary Treatment In Serum Indirect Bilirubin Baseline, Week 12 Proportion Of Participants Who Require Any Increase In Corticosteroid Dose From Baseline To The End Of Follow Up After Primary Treatment Baseline through Week 20 Change In Serum Total Immunoglobulin G (IgG) Levels By Dose Group And Time Point Up to 2 years Time To Hgb Increase By ≥ 2 g/dL From Baseline Baseline through Week 12 Proportion Of Participants Who Require New WAIHA Rescue Medication Or Any Increase In The Dose Of An Existing WAIHA Medication Or pRBC Transfusions For The Treatment Of Anemia Day 15 through Week 12 Change From Baseline To The End Of Primary Treatment In Absolute Reticulocyte Count Baseline, Week 12 Change From Baseline To The End Of Primary Treatment In Serum Haptoglobin Baseline, Week 12 Change In Corticosteroid Dose From The End Of Primary Treatment To The End Of Follow Up Week 12, Week 20 Serum Trough Concentrations Of ALXN1830 Over Time Up to 2 years Change From Baseline Of Albumin By Dose Group And Time Point Up to 2 years Proportion Of Participants Achieving A ≥ 2 g/dL Increase In Hgb From Baseline Through Week 4 Baseline through Week 4 Participants need to achieve this increase without requiring any increase in the dose of an existing WAIHA medication after Day 1 and without pRBC transfusions after Day 14.
Number Of Days To Beginning Of Corticosteroid Taper During Follow Up After Primary Treatment Baseline through Week 20 Taper is defined as the first day that a lower dose of corticosteroids is prescribed/taken.
Number Of Days To Corticosteroid Maintenance Dose During Follow Up After Primary Treatment Baseline through Week 20 Maintenance dose will be defined as \< 10 milligrams (mg)/day of prednisone or equivalent.
Change From Baseline Of IgM By Dose Group And Time Point Up to 2 years
Trial Locations
- Locations (1)
Clinical Study Site
🇺🇸Riverside, California, United States